Better outlook for clinical trials in India

5th August 2015

Better outlook for clinical trials in IndiaGopal Pai

When the Indian government changed the guidance around conducting clinical trials, it put the country out of step with the rest of the world and led to a dramatic drop... Read more

Where does all the PPRS money go?

4th August 2015

Where does all the PPRS money go?Leela Barham

The 2014 Pharmaceutical Price Regulation Scheme (PPRS) includes PPRS payments back from PPRS members to the Department of Health. Leela Barham looks at just where that money goes, drawing on... Read more

7 Questions: Emma Greenwood on advancing research in cancer

3rd August 2015

7 Questions: Emma Greenwood on advancing research in cancerEmma Greenwood

pharmaphorum spoke to the head of policy development at the influential cancer charity about how it is supporting research and increasing the numbers who survive the disease.What prompted you to... Read more

Healthcare communications: hit the reset button

31st July 2015

Healthcare communications: hit the reset button Christian Gardner

In this social media age, when ePatients and bloggers can have the same influence as trade journalists, is it time to abandon traditional methods and apply a fresh approach?What influences... Read more


Shire's $30bn bid for Baxalta faces significant hurdles

5th August 2015

Shire's $30bn bid for Baxalta faces significant hurdlesPhil Taylor

Shire's hostile bid for Baxter spin-out Baxalta would be one of the biggest ever by a UK-listed company but is likely to turn into a protracted struggle.Ireland-based Shire went public... Read more

US FDA approves first 3D-printed drug

4th August 2015

US FDA approves first 3D-printed drugPhil Taylor

An epilepsy treatment developed by Aprecia Pharmaceuticals has become the first drug made using 3D printing to be approved for marketing.The new drug – called Spritam (levetiracetam) – is a... Read more

Roche's Perjeta cleared for early use in breast cancer

3rd August 2015

Roche's Perjeta cleared for early use in breast cancerPhil Taylor

Breast cancer patients in the EU could get treatment with Roche's Perjeta earlier in the course of the disease after the drug was approved for a new indication.The European Medicines... Read more

A yes for Gilead, AbbVie and BMS hepatitis drugs, but NICE restricts u…

29th July 2015

A yes for Gilead, AbbVie and BMS hepatitis drugs, but NICE restricts useAndrew McConaghie

NICE has given the green light to three new hepatitis C treatments, but has specified precisely which patients can receive which drugs, based on the patient's genotypes, and the progression... Read more

Audio & Video

Available on demand: Changing behaviour:…

BrightTALK holding slide 4 22June


Understanding your customers is fundamental to effective communication. Current segmentation strategies draw on ever more detailed information... View more

Available on demand: Effectively using r…



Life sciences companies need to make better use of the insights that real-world data (RWD) can provide in order to improve market... View more

Available on demand: Exclusive debate/we…



The way that physicians want and need to consume information has changed dramatically over recent years and continues to evolve rapidly. Working in... View more

Being Patient-centric is being Family-ce…


Cancer survivor and patient opinion leader Andrew Schorr and his wife Esther Schorr discuss how families should be involved in decision-making around care for patients.... View more

White Papers

Successful biopharma product launches de…

Successful biopharma product launches depend upon market insights – driving competitive advantage through innovationChristian Marcazzo & Robin Munro

A major competitive advantage can be gained by companies that unlock the value hidden in the vast quantity of healthcare data available today – particularly that presented by real-world data.View info

Optimising patient outcomes through phys…

Optimising patient outcomes through physician educationDr James Quekett

Physician education is undergoing a massive change as the volume of advances in therapies and practices increases and the use of digital channels facilitates new forms of scientific exchange. This white... View info

Is pharma brand marketing dead?

Is pharma brand marketing dead?Mark Sales, Fabrice Bourg & Richard Goosey

This comprehensive supplement brings together a series of articles, insights and discussions produced by Kantar Health in order to help stimulate debate and fresh thinking about the future of pharmaceutical... View info

Improved health and wellbeing in COPD

Improved health and wellbeing in COPDAna Maria Arboleda, Clare Maloney & Prof John Weinman

Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating disorder, which, as it progresses, places a significant burden on individuals and those caring for them. This is not only... View info

Further News & Articles

Should DTC marketers put away their marketing hats?

Pharma companies need to put themselves in the patient's shoes and provide clear, helpful content at what... Read more


Top tips for writing the best benefit-risk reports

It is important to stay abreast of the latest requirements in pharmacovigilance in order to meet the needs of the re... Read more


NICE diabetes guidelines still don’t add up, say doctors and pharma company

NICE has re-drafted new guidelines for type 2 diabetes treatments after a major backlash from doctors – but crit... Read more


Sanofi and Regeneron play catch-up in immunotherapy with $1bn alliance

In an attempt to catch up with leaders in the red-hot field of cancer immunotherapy, Sanofi and Regeneron have a... Read more


Teva's $40bn Allergan acquisition adds twist to merger drama

The merger merry-go-round continues to spin, although the three-way drama involving Teva Pharmaceutical Industri... Read more


Personal perspective: living with hepatitis C

On #WorldHepatitisDay we highlight a personal account from a woman in the US diagnosed with hepatitis C and how t... Read more